Investing.comQwen · 实盘不做把握 2/10不做原因:无增量信息
北京时间·🕒 发布 08-26 19:36:39·⟳ 抓取 08-26 19:37:20 +41s·⚡ 决策 08-27 05:35:56 +9h58m·61.5 天前
BridgeBio宣布已上市药物acoramidis(Attruby)的上市后研究ASCEND-ATTR完成首例患者给药
Attruby已获批上市，ASCEND-ATTR是上市后承诺研究的首例给药，属程序性节点而非新催化。无新数据、无监管决定、无收入影响，36个月后才读出。当日股价反跌-1.28%确认市场视为非事件。对$155亿市值无可量化增量，不构成交易机会。
📄 原文Investing.com↗ 原文
BridgeBio doses first patient in acoramidis heart study
Forget Nvidia’s Q2 results. Wall Street is watching this $200 billion exposure PALO ALTO, Calif. - BridgeBio Pharma Inc…
不做 BridgeBio Pharma（BBIO.US）
已上市药物的上市后研究(Phase 3b/4)首例给药是程序性节点，无新数据、无监管里程碑、无收入影响。36个月后才读出主要终点，对$155亿市值无可量化增量。当日股价反跌确认市场视为非事件。不构成交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
BridgeBio的Attruby(acoramidis)已获FDA批准并商业化销售。ASCEND-ATTR是一项150人、36个月的上市后影像学承诺研究，'首例给药'是最低级别的程序性里程碑——不改变监管状态、不产生新数据、不影响收入。按生物医药经验框架，事件未推动资产状态迁移（仍在'已上市'阶段内）。当日BBIO收跌-1.28%、量比0.65，市场完全忽略。无跨市场映射价值（小分子TTR稳定剂，无A股供应链关联）。
🔎 新鲜度:最早出现 2026-08-26 · 扩散 low · price-in 风险 low ↗
消息传播链
- Investing.com AI生成文章转述BridgeBio新闻稿，当日发布。文章标注'generated with the support of AI and reviewed by an editor'，为聚合平台自动化内容，非独家首发。市场反应:BBIO当日收跌-1.28%至$79.37，量比0.65，市场完全忽略
反向证据
- 做多前查反向 · 来源 stock_quote · 日期 2026-08-26 · 影响 invalidates
当日股价反跌-1.28%，量比仅0.65，近20日累计-6.02%，市场完全未将此视为正面催化
检索:BBIO acoramidis ASCEND-ATTR market reaction catalyst
先例如何影响了这次决策
对本次决策的影响:无先例可用，但事件本身为程序性节点（已上市药物的上市后研究首例给药），按生物医药经验框架判断无催化价值，无需先例支持即可得出AVOID结论
方向:无可用先例
涨幅量级:无法校准
形态:无
工具调用 · 历史记录,结果未知(6 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- stock_quote · 结果未知
- web_search · 结果未知
- search_case_library · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,117 字
Forget Nvidia’s Q2 results. Wall Street is watching this $200 billion exposure
PALO ALTO, Calif. - BridgeBio Pharma Inc. (NASDAQ:BBIO) announced today that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study examining the long-term effects of acoramidis on cardiac structure, function, and amyloid burden in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
The study will enroll approximately 150 participants with ATTR-CM. Cardiovascular magnetic resonance and cardiac echocardiography will be performed annually over 36 months, according to a press release statement. The primary efficacy endpoint is responder status at Month 36 based on improvement from baseline in left ventricular systolic function.
Secondary endpoints include measures of cardiac function, structure, and amyloid burden at Month 36, along with echocardiographic measures, circulating biomarkers, and imaging assessments at Months 12 and 24.
The study follows results from the ATTRibute-CM CMR substudy, which showed treatment with acoramidis was associated with changes in cardiac measurements through month 30, including Left Ventricular Mass Index, Left Ventricular Stroke Volume Index, and Left Ventricular Ejection Fraction, with evidence of amyloid regression in a subset of patients.
Acoramidis is marketed as Attruby, a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Additional data from the CMR substudy of ATTRibute-CM and its open-label extension compared to a natural history cohort will be presented at the European Society of Cardiology Congress 2026.
In clinical trials, diarrhea occurred in 11.6% of patients treated with Attruby versus 7.6% on placebo, while upper abdominal pain occurred in 5.5% versus 1.4%, respectively. Discontinuation rates due to adverse events were 9.3% for Attruby and 8.5% for placebo.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
PALO ALTO, Calif. - BridgeBio Pharma Inc. (NASDAQ:BBIO) announced today that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study examining the long-term effects of acoramidis on cardiac structure, function, and amyloid burden in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
The study will enroll approximately 150 participants with ATTR-CM. Cardiovascular magnetic resonance and cardiac echocardiography will be performed annually over 36 months, according to a press release statement. The primary efficacy endpoint is responder status at Month 36 based on improvement from baseline in left ventricular systolic function.
Secondary endpoints include measures of cardiac function, structure, and amyloid burden at Month 36, along with echocardiographic measures, circulating biomarkers, and imaging assessments at Months 12 and 24.
The study follows results from the ATTRibute-CM CMR substudy, which showed treatment with acoramidis was associated with changes in cardiac measurements through month 30, including Left Ventricular Mass Index, Left Ventricular Stroke Volume Index, and Left Ventricular Ejection Fraction, with evidence of amyloid regression in a subset of patients.
Acoramidis is marketed as Attruby, a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Additional data from the CMR substudy of ATTRibute-CM and its open-label extension compared to a natural history cohort will be presented at the European Society of Cardiology Congress 2026.
In clinical trials, diarrhea occurred in 11.6% of patients treated with Attruby versus 7.6% on placebo, while upper abdominal pain occurred in 5.5% versus 1.4%, respectively. Discontinuation rates due to adverse events were 9.3% for Attruby and 8.5% for placebo.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。